The second working meeting of the second session of clinical special committee of China drug promotion association was successfully held

Source: on the afternoon of May 23, 2018, the second working meeting of the second session of the pharmaceutical clinical research committee of China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "the meeting") was held in Hangzhou Song Ruilin, executive chairman of China Association for the promotion of drugs, Ding liming, 2016-2017 president, huoyong, the second chairman of clinical special committee, and nearly 40 vice chairmen and members attended the meeting The meeting was presided over by Chairman Huo Yong, who deliberated and approved the proposal of adding 3 vice chairmen and 5 members of the special clinical Committee After this supplement and adjustment, there are 77 members of the clinical special committee of the Chinese Association for the promotion of drugs (the list of members of the second clinical special committee is attached) Song Ruilin, executive chairman of the China Association for the promotion of drugs, issued a certificate to the newly elected vice chairman, Professor Wu Yilong Director Huo Yong made a report on the work of the special clinical Committee Song Ruilin (left), executive chairman of China Association for the promotion of drugs, took a photo with Wu Yilong (right), the second vice chairman of the special clinical Committee Later, director huoyong reported the main work of the special clinical Committee since this year: 1 Participated in the organization of the GCP and ICH conference At the GCP and ICH conference, a number of chairpersons and vice chairpersons of the clinical special committee delivered a number of keynote speeches on innovative clinical research and the implementation of relevant guidelines of ICH clinical research in China, which provided strong support for the success of the GCP and ICH conference; 2 One of the most important tasks of CFDA this year is to organize the third China pharmaceutical innovation brand selection, i.e "Dushu Lake Cup" pharmaceutical innovation brand selection (hereinafter referred to as "brand selection") A number of experts from the clinical special committee have been selected as the "recommendation and evaluation expert committee" of brand selection, and actively participate in the formulation of brand selection management methods and evaluation standards In order to start Some members of the clinical special committee also participated in the preparation of the 9th China Hospital Pharmaceutical Policy Forum, which will be held in Beijing on July 20 4 Members of China Pharmaceutical Promotion Association Beijing Tiantan Hospital Affiliated to Capital Medical University, in cooperation with the American Cancer Foundation, has established a "brain tumor clinical drug research and development platform", which is of great significance to improve the clinical research level of brain tumors in China and promote the research and development of brain tumor drugs At that time, chairman Huo Yong mobilized all members to actively participate in the preparation of the third China Pharmaceutical Innovation and investment conference, another important work of China Pharmaceutical Council In addition, experts and enterprise members of the clinical institutions also had a heated discussion on the current problems in drug research and clinical research The convening of this meeting deepened the awareness and participation of all members in the work of China drug promotion association and clinical special committee, effectively promoted the in-depth exchanges between enterprises and clinical research institutions on the current development direction and existing problems of drug clinical research, standardized the clinical research for member units under the ICH guiding principles, and helped the strategic layout of drug clinical research in the new situation Conference site